Literature DB >> 28919049

Perioperative outcomes of syndromic paraganglioma and pheochromocytoma resection in patients with von Hippel-Lindau disease, multiple endocrine neoplasia type 2, or neurofibromatosis type 1.

James J Butz1, Qi Yan1, Travis J McKenzie1, Toby N Weingarten2, Alexandre N Cavalcante2, Irina Bancos3, William F Young3, Darrell R Schroeder4, David P Martin2, Juraj Sprung5.   

Abstract

BACKGROUND: Pheochromocytoma and/or paraganglioma associated with neurofibromatosis type 1, multiple endocrine neoplasia type 2A, and von Hippel-Lindau disease have different catecholamine biochemical phenotypes. We examined perioperative outcomes of pheochromocytoma/paraganglioma resection in 3 syndromic forms.
METHODS: Retrospective review of patients undergoing resection of syndromic pheochromocytoma/paraganglioma from 2000 through 2016.
RESULTS: Eighty-one patients underwent pheochromocytoma/paraganglioma resection (multiple endocrine neoplasia type 2A, n = 36; neurofibromatosis type 1, n = 26; von Hippel-Lindau disease, n = 19). Tumor size differed across groups; patients with neurofibromatosis type 1 and von Hippel-Lindau disease had the largest tumors (P = .017). Larger tumor volumes correlated with higher urine 24-hour total metanephrine (r = 0.94, P < .001; r = 0.67, P = .033; and r = 0.89, P < .001 for multiple endocrine neoplasia type 2A, von Hippel-Lindau disease, and neurofibromatosis type 1, respectively). High adrenergic secretion (24-hour urine metanepinephrine) was found in neurofibromatosis type 1 (median, 861 μg/24 h), similar to that found in multiple endocrine neoplasia type 2A (median, 809 μg/24 h). The highest noradrenergic secretion (24-hour urine normetanephrine) occurred with von Hippel-Lindau disease (median, 4,598 μg/24 h), followed by neurofibromatosis type 1 and multiple endocrine neoplasia type 2A (median, 1,607 and 923 μg/24 h, respectively). The highest graded complications occurred among patients with neurofibromatosis type 1 (P = .036). However, when comparing postoperative outcomes across 3 groups in those who had laparoscopic resection, there was no significant difference (P = .955).
CONCLUSION: Patients with neurofibromatosis type 1 had the most volatile intraoperative hemodynamic course and more severe postoperative complications. These complications are related to large tumors associated with abundant catecholamine secretion and the fact that a high proportion underwent open resection. Among only patients who underwent laparoscopic procedures, there were no differences in postoperative outcomes across syndromic groups.
Copyright © 2017 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Year:  2017        PMID: 28919049     DOI: 10.1016/j.surg.2017.08.002

Source DB:  PubMed          Journal:  Surgery        ISSN: 0039-6060            Impact factor:   3.982


  9 in total

1.  Changing pattern of pheochromocytoma and paraganglioma in a stable UK population.

Authors:  I T Cvasciuc; S Gull; R Oprean; K H Lim; F Eatock
Journal:  Acta Endocrinol (Buchar)       Date:  2020 Jan-Mar       Impact factor: 0.877

2.  International Society of Paediatric Surgical Oncology (IPSO) Surgical Practice Guidelines.

Authors:  Simone de Campos Vieira Abib; Chan Hon Chui; Sharon Cox; Abdelhafeez H Abdelhafeez; Israel Fernandez-Pineda; Ahmed Elgendy; Jonathan Karpelowsky; Pablo Lobos; Marc Wijnen; Jörg Fuchs; Andrea Hayes; Justin T Gerstle
Journal:  Ecancermedicalscience       Date:  2022-02-17

3.  Screening for Hereditary Pheochromocytoma in a Patient with Neurofibromatosis Type 1: A Case Report.

Authors:  Inês Isabel Ferreira Barros; Fernando Manso; Ana Isabel Caldas E Silva; Maria Ramires Silva Lopes Pereira
Journal:  touchREV Endocrinol       Date:  2021-04-28

Review 4.  Advances in adrenal tumors 2018.

Authors:  J Crona; F Beuschlein; K Pacak; B Skogseid
Journal:  Endocr Relat Cancer       Date:  2018-07       Impact factor: 5.678

5.  Phaeochromocytoma/paraganglioma and adverse clinical outcomes in patients with neurofibromatosis-1.

Authors:  Ahmed Al-Sharefi; Petros Perros; Robert Andrew James
Journal:  Endocr Connect       Date:  2018-08-17       Impact factor: 3.335

6.  Hemodynamic instability during percutaneous ablation of extra-adrenal metastases of pheochromocytoma and paragangliomas: a case series.

Authors:  Atousa Deljou; Jacob D Kohlenberg; Toby N Weingarten; Irina Bancos; William F Young; Darrell R Schroeder; David P Martin; Juraj Sprung
Journal:  BMC Anesthesiol       Date:  2018-11-06       Impact factor: 2.217

7.  Clinical Presentation and Outcomes of Phaeochromocytomas/Paragangliomas in Neurofibromatosis Type 1.

Authors:  Ahmed Al-Sharefi; Usman Javaid; Petros Perros; John Ealing; Peter Truran; Sath Nag; Shafie Kamaruddin; Kamal Abouglila; Fiona Cains; Lauren Lewis; Robert Andrew James
Journal:  Eur Endocrinol       Date:  2019-08-16

8.  Phase II Clinical Trial of Pembrolizumab in Patients with Progressive Metastatic Pheochromocytomas and Paragangliomas.

Authors:  Camilo Jimenez; Vivek Subbiah; Bettzy Stephen; Junsheng Ma; Denai Milton; Mingxuan Xu; Abdualrazzak Zarifa; Fechukwu Omolara Akhmedzhanov; Apostolia Tsimberidou; Mouhammed Amir Habra; Jordi Rodon Anhert; Siqing Fu; Aung Naing
Journal:  Cancers (Basel)       Date:  2020-08-16       Impact factor: 6.639

9.  Maternal and fetal outcomes in phaeochromocytoma and pregnancy: a multicentre retrospective cohort study and systematic review of literature.

Authors:  Irina Bancos; Elizabeth Atkinson; Charis Eng; William F Young; Hartmut P H Neumann
Journal:  Lancet Diabetes Endocrinol       Date:  2020-11-26       Impact factor: 32.069

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.